SEC Form 4 · accession 0001209191-16-110143
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Chaplin
Officer — Chief Scientific Officer · Director
Period of report
Mar 21, 2016
Accepted (ET)
Mar 23, 2016 · 9:06 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.7277 | Mar 21, 2016 | A | 262,500 | A | — | Mar 21, 2026 | Common Stock | 262,500 | 262,500 | D |
Explanation of responses
- F1Dr. Chaplin was awarded options to purchase shares of OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options"), pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Scientific Officer.
- F225% of the Stock Options will vest on the first anniversary of the date of grant, and the remainder will vest in 36 substantially equal monthly installments beginning one year and one month after the grant date.